COMP <GO>
VCEL vs RXRX // EV/EBITDA & P/E VALUATION
Vericel Corporation (NASDAQ) VS. Recursion Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: VCEL 7
— RXRX 4
■ METRIC PARITY
LAST: $40.51 (+0.62%) • MKT CAP: $2.06B
valuation
61.4x
LAST: $3.83 (-4.96%) • MKT CAP: $2.41B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VCEL VS. RXRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VCEL | RXRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.40% | 5.00% | +69.40 | VCEL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.40% | -35.00% | +38.40 | VCEL | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 61.4x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.13% | -14.95% | +16.08 | VCEL | /fcf-yield <GO> |
| Operating Margin | 4.00% | -60.00% | +64.00 | VCEL | /operating-margins <GO> |
| Net Profit Margin | 6.00% | -60.00% | +66.00 | VCEL | /net-margins <GO> |
| Revenue Growth (YoY) | 16.50% | 26.90% | -10.40 | RXRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.94 | 1.59 | +8.35 | VCEL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 4/9 | +4.00 | VCEL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.8 | 51.7 | -4.90 | RXRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.00 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 111.7x | 32.0x | +79.70 | RXRX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.06B | $2.41B | -$343.9M | RXRX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VCEL REV | RXRX REV | VCEL GROSS % | RXRX GROSS % | VCEL FCF | RXRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $276.3M | $74.7M | 74.4% | 5.0% | $24.7M | -$378.3M |
| FY 2024 | $237.2M | $58.8M | 72.6% | 23.1% | -$5.8M | -$372.9M |
| FY 2023 | $197.5M | $44.6M | — | — | $35.3M | -$289.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VCEL // BETA —
RXRX // BETA 1.00